Literature DB >> 17646191

Comorbidity, healthcare utilisation and process of care measures in patients with congenital heart disease in the UK: cross-sectional, population-based study with case-control analysis.

J Billett1, M R Cowie, M A Gatzoulis, I F Vonder Muhll, A Majeed.   

Abstract

OBJECTIVE: To determine the prevalence of comorbidities, patterns of healthcare utilisation and primary care recording of clinical indicators in patients with congenital heart disease. PATIENTS AND METHODS: A population-based case-control study using data from general practices across the UK contributing data to the QRESEARCH primary care database. The subjects comprised 9952 patients with congenital heart disease and 29,837 matched controls. Outcome measures were prevalence of selected comorbidities; adjusted odds ratios for risk of comorbidities, healthcare utilisation and clinical indicator recording.
RESULTS: The overall crude prevalence of congenital heart disease was 3.05 per 1000 patients (95% CI 2.99 to 3.11). Prevalence of key comorbidities in patients with congenital heart disease ranged from 2.4% (95% CI 2.1% to 2.7%) for epilepsy to 9.3% (95% CI 8.8% to 9.9%) for hypertension. After adjusting for smoking and deprivation, cases were significantly more likely than controls to have each of the cardiovascular comorbidities and an increased risk of diabetes, epilepsy and renal disease. Patients with congenital heart disease were more frequent users of primary care than controls. Patients with congenital heart disease were also more likely than controls to have lifestyle and risk factor measurements recorded in primary care, although overall levels of recording were low.
CONCLUSIONS: There is a significant burden of comorbidity associated with congenital heart disease, and levels of primary care utilisation and referral to secondary care are high in this patient group. The predicted future expansion in the numbers of adults with congenital heart disease owing to improvements in survival will have implications for primary and secondary care, and not just tertiary centres offering specialist care.

Entities:  

Mesh:

Year:  2007        PMID: 17646191     DOI: 10.1136/hrt.2007.122671

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  47 in total

1.  Premature death in adults with 22q11.2 deletion syndrome.

Authors:  A S Bassett; E W C Chow; J Husted; K A Hodgkinson; E Oechslin; L Harris; C Silversides
Journal:  J Med Genet       Date:  2009-02-25       Impact factor: 6.318

2.  Transition and transfer from pediatric to adult care of young adults with complex congenital heart disease.

Authors:  Alison Knauth Meadows; Valerie Bosco; Elizabeth Tong; Susan Fernandes; Arwa Saidi
Journal:  Curr Cardiol Rep       Date:  2009-07       Impact factor: 2.931

3.  Complex congenital heart disease in unaffected relatives of adults with 22q11.2 deletion syndrome.

Authors:  Jodi-Ann M Swaby; Candice K Silversides; Sean C Bekeschus; Sara Piran; Erwin N Oechslin; Eva W C Chow; Anne S Bassett
Journal:  Am J Cardiol       Date:  2011-02-01       Impact factor: 2.778

4.  Extra-cardiac comorbidities or complications in adults with congenital heart disease: a nationwide inpatient experience in the United States.

Authors:  Sandeep Singh; Rupak Desai; Hee Kong Fong; Ashish Sadolikar; Suparn Samani; Hemant Goyal
Journal:  Cardiovasc Diagn Ther       Date:  2018-12

Review 5.  CSI position statement on management of heart failure in India.

Authors:  Santanu Guha; S Harikrishnan; Saumitra Ray; Rishi Sethi; S Ramakrishnan; Suvro Banerjee; V K Bahl; K C Goswami; Amal Kumar Banerjee; S Shanmugasundaram; P G Kerkar; Sandeep Seth; Rakesh Yadav; Aditya Kapoor; Ajaykumar U Mahajan; P P Mohanan; Sundeep Mishra; P K Deb; C Narasimhan; A K Pancholia; Ajay Sinha; Akshyaya Pradhan; R Alagesan; Ambuj Roy; Amit Vora; Anita Saxena; Arup Dasbiswas; B C Srinivas; B P Chattopadhyay; B P Singh; J Balachandar; K R Balakrishnan; Brian Pinto; C N Manjunath; Charan P Lanjewar; Dharmendra Jain; Dipak Sarma; G Justin Paul; Geevar A Zachariah; H K Chopra; I B Vijayalakshmi; J A Tharakan; J J Dalal; J P S Sawhney; Jayanta Saha; Johann Christopher; K K Talwar; K Sarat Chandra; K Venugopal; Kajal Ganguly; M S Hiremath; Milind Hot; Mrinal Kanti Das; Neil Bardolui; Niteen V Deshpande; O P Yadava; Prashant Bhardwaj; Pravesh Vishwakarma; Rajeeve Kumar Rajput; Rakesh Gupta; S Somasundaram; S N Routray; S S Iyengar; G Sanjay; Satyendra Tewari; Sengottuvelu G; Soumitra Kumar; Soura Mookerjee; Tiny Nair; Trinath Mishra; U C Samal; U Kaul; V K Chopra; V S Narain; Vimal Raj; Yash Lokhandwala
Journal:  Indian Heart J       Date:  2018-06-08

6.  How often is congenital heart disease recognized as a significant comorbidity among hospitalized adults with congenital heart disease?

Authors:  James M Robbins; Jennifer Onukwube; Anthony Goudie; R Thomas Collins
Journal:  Int J Cardiol       Date:  2017-02-22       Impact factor: 4.164

7.  Elucidating the diagnostic odyssey of 22q11.2 deletion syndrome.

Authors:  Lisa D Palmer; Nancy J Butcher; Erik Boot; Kathleen A Hodgkinson; Tracy Heung; Eva W C Chow; Alina Guna; T Blaine Crowley; Elaine Zackai; Donna M McDonald-McGinn; Anne S Bassett
Journal:  Am J Med Genet A       Date:  2018-04       Impact factor: 2.802

Review 8.  Preoperative Evaluation of Adult Congenital Heart Disease Patients for Non-cardiac Surgery.

Authors:  Jennifer F Gerardin; Michael G Earing
Journal:  Curr Cardiol Rep       Date:  2018-07-21       Impact factor: 2.931

Review 9.  Brain in Congenital Heart Disease Across the Lifespan: The Cumulative Burden of Injury.

Authors:  Ariane Marelli; Steven P Miller; Bradley Scott Marino; Angela L Jefferson; Jane W Newburger
Journal:  Circulation       Date:  2016-05-17       Impact factor: 29.690

10.  Kidney Outcomes 5 Years After Pediatric Cardiac Surgery: The TRIBE-AKI Study.

Authors:  Jason H Greenberg; Michael Zappitelli; Prasad Devarajan; Heather R Thiessen-Philbrook; Catherine Krawczeski; Simon Li; Amit X Garg; Steve Coca; Chirag R Parikh
Journal:  JAMA Pediatr       Date:  2016-11-01       Impact factor: 16.193

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.